Kyeong-Ryoon Lee
Overview
Explore the profile of Kyeong-Ryoon Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee K, Gulnaz A, Chae Y
Pharmaceutics
. 2024 Nov;
16(11).
PMID: 39598554
Inflammatory bowel disease (IBD) is a complex and chronic condition that requires the use of various pharmacological agents for its management. Despite advancements in IBD research, the multifaceted mechanisms involved...
2.
Kang M, Lee K, Choi Y, Chae Y
Nat Prod Res
. 2024 Nov;
:1-9.
PMID: 39497580
Multidrug resistance is a crucial factor contributing to the failure of cancer treatment. Multidrug resistance protein 1 (MDR1) is the most relevant efflux transporter associated with multidrug resistance. The objective...
3.
Koo N, Lee E, Kim M, Park M, Lee K, Chae Y
Heliyon
. 2024 Oct;
10(19):e38637.
PMID: 39403541
Ponatinib is a potent tyrosine kinase inhibitor that is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. To further expand its clinical applications, accurate...
4.
Kang M, Kim M, Seol Y, Chang J, Lee K, Chae Y
Biomed Pharmacother
. 2024 Jul;
178:117114.
PMID: 39053425
Bosutinib has been approved for use in patients with chronic myeloid leukemia. Information regarding the effects of bosutinib on clinically important drug transporters is limited, particularly regarding its inhibitory potency...
5.
Kim H, Ryu C, Lee M, Lee K, Kim J
Adv Ther
. 2024 Jun;
41(7):2936-2952.
PMID: 38833144
Introduction: Hair loss is driven by multiple factors, including genetics. Androgenetic alopecia (AGA) is a condition in which treatments necessitate prolonged compliance with prescribed medications. We have developed IVL3001, a...
6.
Yang J, Shin D, Jeong M, Kim S, Jeong H, Lee B, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794236
The blood-brain-barrier (BBB) is made up of blood vessels whose permeability enables the passage of some compounds. A predictive model of BBB permeability is important in the early stages of...
7.
Gulnaz A, Lee K, Kang M, Chang J, Chae Y
Toxicol Lett
. 2024 Feb;
394:57-65.
PMID: 38423481
Drug transporters are among the factors that determine the pharmacokinetic profiles after drug administration. In this study, we investigated the roles of drug transporters involved in transport of SN-38, which...
8.
Kang M, Kim M, Kim A, Koo T, Lee K, Chae Y
Chem Biol Interact
. 2024 Jan;
390:110886.
PMID: 38280639
Niclosamide is an anthelmintic drug with a long history of use and is generally safe and well tolerated in humans. As the conventional dose of niclosamide results in a low...
9.
Choi Y, Choe H, Kook M, Choo S, Park T, Bae S, et al.
J Med Chem
. 2023 Dec;
67(3):1825-1842.
PMID: 38124427
The outer membrane (OM) of Gram-negative bacteria is the most difficult obstacle for small-molecule antibiotics to reach their targets in the cytosol. The molecular features of Gram-negative antibiotics required for...
10.
Yun T, Jeong J, Koo Y, Chae Y, Lee D, Kim H, et al.
In Vivo
. 2023 Aug;
37(5):2128-2133.
PMID: 37652477
Background/aim: Fingolimod is a sphingosine-1-phosphate receptor modulator that prevents lymphocytes egress from lymphoid organs. It has been used as a disease-modifying drug for human multiple sclerosis and has shown better...